# Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

> **NCT03061656** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- High Risk Neuroblastoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **RADIATION:** 131I-MIBG
- **DRUG:** Thiotepa
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT03061656
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01-01
- **Primary completion:** 2013-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061656, "Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03061656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*